• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Movano Inc.

    3/31/25 4:30:04 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    NT 10-K 1 ea0236327-nt10k_movano.htm NOTIFICATION OF LATE FILING

    SEC File Number

    001-40254

    CUSIP Number

    62459M107

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    FORM 12b-25

     

     

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
       
      For Period Ended: December 31, 2024
       
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
       
      For the Transition Period Ended:

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

    Part I - Registrant Information

     

    Full Name of Registrant: Movano Inc.
    Former Name if Applicable: Not applicable.

    Address of Principle Executive Office

     

    (Street and Number):

     

    6800 Koll Center Parkway
    City, State and Zip Code: Pleasanton, CA 94566

     

     

     

     

    Part II - Rules 12b-25(b) and (c)

     

     

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ☒

     

    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    Part III - Narrative

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Movano Inc.’s (the “Company”) annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) cannot be filed by the prescribed due date without unreasonable effort and expenses because the Company requires additional time to complete certain items with respect to the financial statements to be included in the Form 10-K. The Company believes that the work in connection with compiling the financial information for the Form 10-K will be completed within the extension period.

     

    In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company anticipates that it will file its Form 10-K as soon as practicable and expects to file within the extension period.

     

    Part IV - Other Information

     

    (1) Name and telephone number of person to contact in regard to this notification

     

      J. Cogan   415   651-3172
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    2

     

     

    SIGNATURE

     

    Movano Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

      Movano Inc.
       
      By:  /s/ J. Cogan
        J. Cogan
    Date: March 31, 2025   Chief Financial Officer

     

     

     

     

    3

     

     

    Get the next $MOVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/12/24 4:30:19 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:08 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

      PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

      5/23/25 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value

      PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.  To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the

      5/16/25 4:30:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements

      Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea

      4/22/25 8:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      4/10/24 4:39:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Movano Inc. (Amendment)

      SC 13G/A - Movano Inc. (0001734750) (Subject)

      4/9/24 5:41:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      2/4/22 4:20:05 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    SEC Filings

    See more
    • Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Movano Inc. (0001734750) (Filer)

      5/23/25 4:05:24 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by Movano Inc.

      NT 10-Q - Movano Inc. (0001734750) (Filer)

      5/21/25 5:22:02 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Movano Inc. (0001734750) (Filer)

      5/19/25 8:48:13 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Financials

    Live finance-specific insights

    See more

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Movano Health Reports Q3 2024 Financial Results and Provides Business Update

      Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

      11/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Reports Q2 2024 Financial Results and Provides Business Update

      Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

      8/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Provides Progress Update on EvieMED Regulatory Filing

      Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

      8/5/24 9:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Caballero Ruben was granted 43,605 shares, increasing direct ownership by 816% to 48,952 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO Cogan Jeremy was granted 62,986 shares, increasing direct ownership by 121% to 115,028 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Mastrototaro John was granted 77,521 shares, increasing direct ownership by 399% to 96,964 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care